Longterm followup of quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab, an anti-interleukin 1β monoclonal antibody

Journal of Rheumatology

Volumn 41, Issue 8, 2014, Pages 1721-1722

  Marsaud, Céline ^a   Marie, Isabelle ^a   Koné Paut, Isabelle ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ADULT; CINCA SYNDROME; CLINICAL ARTICLE; DRUG TOLERABILITY; FOLLOW UP; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; GENE; GENE MUTATION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INJECTION SITE REACTION; LETTER; LONG TERM CARE; LONGITUDINAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NLPR3 GENE; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SOCIAL INTERACTION; UNSPECIFIED SIDE EFFECT; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DOSE RESPONSE; IMMUNOLOGY; MIDDLE AGED; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-1BETA; LONGITUDINAL STUDIES; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84905500871     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131291     Document Type: Letter

References (7)

1. Shinkai K, McCalmont TH, Leslie KS. Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 2008;33:1-9.
2. Stych B, Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives. Curr Med Res Opin 2008;24:1577-82.
3. Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 2010;21:157-63.
4. Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep 2011;11:12-20.
5. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
6. Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011;13:R202.
7. Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Insalaco A, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther 2013;15:R33.